The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
复制标题
DOI：
10.1530/eje-07-0043
复制
发表时间：
2007-08-01
影响因子：
5.8
通讯作者：
Cha, Bong-Soo
中科院分区：
文献类型：
--
作者：
Soo-Kyung, Kim;Hur, Kyu-Yeon;Cha, Bong-Soo
目的：目的是探讨罗格列酮的降血糖作用和2型糖尿病patients.Design和方法的区域性肥胖的变化之间的相互关系：我们加入罗格列酮（4毫克/天）173例糖尿病患者（111名男性和62名女性）已经采取了稳定剂量的常规降糖药物，除了噻唑烷二酮类。在基线和12周后通过超声检查评估腹部脂肪分布。使用超声图像，s.c.结果：罗格列酮治疗3个月后，血糖控制明显改善。然而，罗格列酮的有效率不超过36.41%; 16.8%的受试者血糖控制恶化。此外，罗格列酮治疗显著增加了体脂肪量，尤其是皮下脂肪。胖了然而，这并没有改变内脏脂肪含量。治疗后空腹血糖（FPG）和糖化血红蛋白（HbA 1c）变化百分比与SFT升高呈负相关（r=-0.327和-0.353，P均< 0.001）。与体重的相关系数分别为-0.31.6和-0.327，P < 0.001。多元回归分析显示，罗格列酮治疗后FPG的改善与基线FPG相关（P < 0.001）和SFT的变化（P=0.019），HbA 1c的降低与基线FPG相关SFT（P = 0.010）和VFT（P =0.013）的变化。罗格列酮治疗后脂肪沉积可能是决定降血糖疗效的独立因素。
Objective: The goal was to investigate the interrelationships between the hypoglycemic effects of rosiglitazone and the changes in the regional adiposity of type 2 diabetic patients.Design and methods: We added rosiglitazone (4 mg/day) to 173 diabetic patients (111 males and 62 females) already taking a stable dose of conventional antidiabetic medications except for thiazolidinediones. The abdominal fat distribution was assessed by ultrasonography at baseline and 12 weeks later. Using ultrasonographic images, the s.c. and visceral fat thickness (SFT and VFT respectively) were measured.Results: Rosiglitazone treatment for 3 months improved the glycemic control. However, the response to rosiglitazone was no more than 36.41%; the deterioration of the glycemic control was found in 16.8% of subjects. In addition, rosiglitazone treatment significantly increased the body fat mass, especially the s.c. fat. However that did not alter the visceral fat content. The percentage changes in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) concentrations after treatment were inversely correlated with the increase in SFT (r=-0.327 and -0.353, P < 0.001. respectively) and/or body weight (r= -0.31.6 and -0.327, P < 0.001 respectively). Multiple regression analysis revealed that the improvement in the FPG after rosiglitazone treatment was correlated with the baseline FPG (P < 0.001) and the change in the SFT (P=0.019), and the reduction in the HbA1c was related with the baseline FPG (P=0.003) and HbA1c (P < 0.001) and the changes in the SFT (P=0.010) or VFT (P=0.013).Conclusions: The increase in the s.c. fat depot after rosiglitazone treatment may be an independent factor that determines the hypoglycemic efficacy.